To evaluate whether 4D US guidance (4D biopsy mode) in RFA therapy is effective, we conducted percutaneous RFA using a newly developed 4D-US probe for 5 subjects (5 HCC lesions) between January and May 2011. We used Aplio XG (Toshiba Medical Systems) as the US system and PVT-375MV (3.5MHz) as the newly developed 4D US probe. RFA needle was inserted into the target lesion under 4D US guidance (biopsy mode). Using 4D biopsy mode, we could simultaneously confirm whether the needle tip inserted at the center of the target from two different sections in all cases: therefore, adequate RFA efficiency could be achieved in all 5 subjects. Using a real-time 4D US device for RFA, more accurate insertion could be achieved and more effective therapy could be performed. Therefore, 4D US would be a more useful tool for RFA therapy.
抄録全体を表示